As 2021 draws to a close, it’s clear that several major factors —the full effect of which we may not fully grasp until sometime in the future— are drastically impacting PTAB practice.

The Arthrex decision is perhaps the most iconoclastic of these developments, as it questioned the constitutionality of APJ appointments, thus leaving  unresolved questions which may affect pending and future IPRs as well as previous IPR decisions. Arthrex also gives unprecedented discretionary authority to the PTO Director, who still at this time has yet to be appointed.

There are also ongoing questions about discretionary denials and the future direction of IPRs. All proving that PTAB Practice is still a work in progress, and its related jurisprudence is still evolving.

Attend ACI’s inaugural PTAB Briefing for in depth-discussions and year-end analysis of these most significant developments impacting PTAB practice as well as future forecasts for 2022.

Confirmed U.S. PTAB APJs
Speaker Name

Honorable Stacey G. White

Lead Administrative Patent Judge
Patent and Trial Board, USPTO

Speaker Name

Honorable Ken Barrett

Administrative Patent Judge
Patent and Trial Board, USPTO

Speaker Name

Honorable Phil Kauffman

Administrative Patent Judge
Patent and Trial Board, USPTO

Speaker Name

Efrain Staino

Vice President, IP Litigation
Xperi Corporation (San Francisco, CA)

Who You Will Meet

PTAB Practitioners, including:

  • In-house patent and IP counsel from a variety of industries and areas, including:
    • Electronics
    • Computers and Software
    • Technology
    • Medical Devices
    • Pharmaceuticals and Biotechnology
    • Chemical

 

  • Private practice attorneys in the fields of:
    • Intellectual Property/Patents Litigation
    • USPTO Practice